$TLRY $CGC $ACB $CRON: Cannabis Rescheduling Watch — Why the Anti-Schedule III Case Matters Before the DEA’s July 15 Deadline

Cannabis investors often reduce the federal rescheduling story to one sentence: Schedule III would be bullish. That may be directionally true for sentiment, taxation and access to capital, but it is too thin for anyone trying to understand the real catalyst. The current DEA hearing is not a stock promotion event. It is a formal administrative proceeding designed to receive factual evidence and expert opinion on whether marijuana should be transferred from Schedule I to Schedule III under the Controlled Substances Act.

That distinction matters. Schedule III is not federal legalization. It does not automatically create national adult-use commerce. It does not erase every banking, exchange-listing, state-federal conflict or enforcement problem that cannabis operators have faced for years. What it can do, if finalized broadly enough, is change the federal classification framework, reshape tax treatment under Internal Revenue Code Section 280E for covered businesses, improve the institutional narrative around medical use and potentially open a cleaner path for research, financing and regulated medical operations.

1. What the DEA hearing is actually about

The current proceeding follows the Department of Justice’s earlier proposal to transfer marijuana from Schedule I to Schedule III under the Controlled Substances Act. The original proposal was published in the Federal Register in May 2024 and was based on the view that marijuana has a currently accepted medical use, a lower abuse potential than substances in Schedules I and II, and a dependence profile compatible with Schedule III treatment.

In April 2026, a new notice of hearing reset the administrative process. The Federal Register notice stated that DEA would hold a hearing beginning June 29, 2026, that the hearing would conclude not later than July 15, 2026, and that the purpose of the hearing was to receive factual evidence and expert opinion regarding whether marijuana should be transferred to Schedule III.

This is why the current story is not merely political. The administrative record matters. The record is what the agency, the Administrative Law Judge and any reviewing court may later examine. A headline can move a cannabis stock for a day. A durable regulatory shift has to survive the machinery of administrative law.

2. Schedule I vs. Schedule III: the legal hinge

Under the Controlled Substances Act, Schedule I is reserved for substances with a high potential for abuse, no currently accepted medical use in treatment in the United States and a lack of accepted safety for use under medical supervision. Schedule III is different. A Schedule III substance has a lower abuse potential than substances in Schedules I and II, has a currently accepted medical use in treatment in the United States, and its abuse may lead to moderate or low physical dependence or high psychological dependence.

That is the heart of the fight. The rescheduling case does not require proving that marijuana is harmless. It does not require proving that every cannabis product in every state program is medically ideal. It requires a legal and scientific conclusion that marijuana fits Schedule III better than Schedule I under the CSA framework.

3. Why cannabis stocks care: the 280E and sentiment layer

For publicly traded cannabis names such as $TLRY, $CGC, $ACB and $CRON, the immediate market reaction to rescheduling headlines is usually driven by three expectations: tax relief, better institutional perception and a more credible federal medical framework. The tax component is the most concrete.

Section 280E of the Internal Revenue Code generally disallows deductions and credits for businesses trafficking in Schedule I or Schedule II controlled substances prohibited by federal or state law. Treasury and the IRS have stated that rescheduling generally removes Section 280E as a bar to claiming deductions and credits for businesses that, as a result of the final order, no longer traffic in Schedule I or II substances under the CSA.

This does not mean every cannabis operator receives the same benefit at the same time. The April 2026 medical marijuana action created a narrower medical track, while the broader hearing concerns whether all marijuana should move from Schedule I to Schedule III. Adult-use operators, multi-state structures, mixed medical/adult-use revenue, state licensing details and final IRS guidance all matter.

4. The hearing calendar: where the anti-rescheduling case enters

DEA selected a small group of interested persons to participate in the hearing. The list includes the National Drug & Alcohol Screening Association, the Tennessee Bureau of Investigation, Smart Approaches to Marijuana, the States of Nebraska, Idaho, Indiana and initially Louisiana, DUID Victim Voices, Kenneth Finn, M.D., and Phillip A. Drum, PharmD. Louisiana later withdrew, so the state bloc should now be understood as Nebraska, Idaho and Indiana.

The schedule is useful because it shows when the opposition case comes into view. The Government opened first. NDASA began on July 2. SAM, probably the most important anti-rescheduling participant from a scientific and legal messaging standpoint, begins its case on July 6. DUID Victim Voices, Kenneth Finn, TBI, Phillip Drum and the remaining state participants follow before the July 15 deadline.

5. Why SAM is the key anti-Schedule III participant

Smart Approaches to Marijuana is important because its prehearing statement attacks the Schedule III thesis directly. SAM says it intends to call Dr. Bertha K. Madras, a professor in the Department of Psychiatry at Harvard Medical School, as an expert witness. The anticipated testimony is not framed as a generic moral objection. It is framed as a statutory argument: marijuana allegedly has a high potential for abuse, has no currently accepted medical use, and lacks accepted safety for use under medical supervision.

SAM’s filing also states that it intends to call Dr. Luli R. Akinfiresoye as an expert witness. This matters because SAM is not relying only on a public-policy argument; it is attempting to build a scientific and procedural challenge to the Government’s Schedule III record.

That framing matters because it mirrors the legal architecture of Schedule I. If SAM can persuade the record that any of those pillars remains unresolved, the broader Schedule III case becomes more vulnerable. The market may focus on whether the hearing “sounds bullish” or “sounds bearish,” but the cleaner question is whether the government’s scientific record remains strong after cross-examination and rebuttal.

5.1 Abuse potential

SAM’s prehearing statement says Dr. Madras is expected to testify that marijuana abuse and addiction are serious societal problems and that rescheduling would increase availability. This is a direct challenge to the finding that marijuana’s abuse potential is lower than Schedule I and II comparators. The opposition does not need to show that marijuana is more dangerous than every Schedule I or II substance. It needs to create doubt around the relative-abuse analysis used by HHS/FDA and DOJ.

This is where the hearing may become technical. HHS and FDA have treated abuse potential as a comparative assessment across multiple epidemiological indicators, including serious outcomes, emergency events, poison-center metrics and overdose comparisons. Opponents may focus on prevalence, daily use, youth exposure, cannabis use disorder and high-THC products. Both sides can talk about “abuse potential” while emphasizing different datasets and different definitions of harm.

5.2 CAMU: currently accepted medical use

CAMU is probably the center of gravity. Historically, DEA has looked heavily at FDA approval or a strict medical-use test. The more recent HHS/FDA approach considered widespread medical use under state-authorized programs and credible scientific support for such use. That is a major conceptual shift. Supporters of rescheduling see it as a realistic way to evaluate modern state medical cannabis systems. Opponents see it as a dilution of traditional drug-approval standards.

This is not a semantic dispute. If CAMU requires a conventional FDA-approved botanical marijuana product, the rescheduling case is harder. If CAMU can be supported by broad medical use under state programs plus credible scientific evidence, the Schedule III case becomes much more plausible.

5.3 Safety under medical supervision

SAM’s case also targets accepted safety. That argument can include THC variability, product potency, psychiatric risk, risks to adolescents and pregnancy, drug interaction questions, lack of standardized dosing, differences between state programs, and the gap between dispensary products and conventional FDA-approved medicines.

The government’s likely answer is that Schedule III does not require proving marijuana is risk-free. It requires a finding that the substance fits Schedule III’s abuse and dependence profile and has a currently accepted medical use. The difference between those two standards is crucial. In policy debate, people often ask whether cannabis is safe in an absolute sense. In CSA scheduling, the question is relative and statutory.

6. The Government’s case: FDA, the 8-factor analysis and medical-use testimony

The Government’s prehearing statement identifies Dominic Chiapperino, Ph.D., Director of the Controlled Substance Staff at FDA’s Center for Drug Evaluation and Research, and Corey Burchman, M.D., as proposed witnesses. Dr. Chiapperino is expected to testify about the FDA-supported 8-factor analysis and FDA’s assessment of marijuana’s currently accepted medical use. The statement says he is expected to testify to the findings necessary to support placement in Schedule III: lower abuse potential than Schedule I and II substances, CAMU for at least one therapeutic condition, and a dependence profile consistent with Schedule III.

Dr. Burchman is expected to testify as a medical expert with pain-management experience and clinical experience involving medical marijuana. The government statement indicates that he will discuss medical benefit for pain patients and patient safety measures used in the medical marijuana industry, including caps on monthly amounts, product QR codes, certificates of analysis and certified lab testing, with reference to the New Hampshire medical marijuana model.

7. The opposition groups: not all anti cases are the same

It would be a mistake to treat every anti-rescheduling participant as identical. Some are likely to focus on clinical risk. Others are likely to focus on workplace testing, road safety, law enforcement, diversion or the legal definition of accepted medical use. For a reader tracking cannabis equities, the difference matters because only some of these arguments go directly to the legal test for Schedule III.

8. The key nuance: public-safety problems are real, but not all of them defeat Schedule III

Cannabis policy debates often collapse several questions into one. Is cannabis safe? Should adult-use markets exist? Should impaired driving be punished? Should employers be allowed to test? Should dispensary products have stronger labeling and potency controls? Should the federal government recognize medical cannabis? These are related questions, but they are not the same question.

The DEA hearing is centered on scheduling. Public-safety arguments can be relevant if they inform abuse potential, dependence, safety under medical supervision or the regulatory consequences of rescheduling. But a practical concern does not automatically defeat Schedule III. Many Schedule III substances can be abused, require controls, carry risk, and still have accepted medical use.

This is where the government’s framing matters. A move to Schedule III would not remove all controls. It would still keep marijuana within the CSA. It would still leave manufacture, distribution, dispensing and possession subject to applicable criminal prohibitions and regulatory requirements. The Federal Register’s 2024 proposal specifically noted that if marijuana were transferred to Schedule III, regulatory controls applicable to Schedule III substances would apply, along with existing marijuana-specific requirements and any additional controls needed to meet treaty obligations.

9. What would be bullish for the cannabis sector

A constructive hearing outcome for cannabis equities would not require every opponent to concede. It would require the government’s record to remain credible, coherent and legally defensible. The cleaner the government’s evidence appears on CAMU, abuse potential and Schedule III dependence profile, the more the market may treat the July 15 endpoint as a stepping stone toward final broad rescheduling.

10. What would be bearish or at least cautionary

The bearish case is not simply “SAM speaks.” Opponents were always expected. The real risk is that anti-rescheduling testimony creates a record that gives DEA, DOJ or a later court reason to slow the process, narrow the rule, require additional explanation or expose the final rule to stronger legal challenge.

11. The ticker lens: $TLRY, $CGC, $ACB, $CRON and $MSOS

For traders, the cannabis rescheduling story often expresses itself through a small group of liquid cannabis proxies. $TLRY, $CGC, $ACB and $CRON remain among the tickers that retail traders tend to monitor when U.S. cannabis-policy headlines appear. $MSOS is frequently watched as a U.S. cannabis-sector ETF proxy. The point is not that each company has the same exposure or the same financial profile. They do not. The point is that policy headlines can move the entire cannabis tape through sentiment, short interest, liquidity pockets and sector-wide positioning.

The more sophisticated question is whether the move is merely a headline rally or a change in the fundamental probability tree. A broad Schedule III final rule with a credible tax pathway would be more meaningful than another vague “hearing underway” headline. Conversely, a messy hearing record or credible litigation risk could produce a familiar cannabis-stock pattern: fast optimism, faster fade, and renewed skepticism once traders realize the legal process is not finished.

12. The most important dates to monitor

The next phase is about the hearing record. SAM’s case beginning July 6 is particularly important because it is the cleanest anti-Schedule III argument on the calendar. The closing phase on July 15 matters because DEA has said the hearing will conclude not later than that date, although transcripts and later procedural actions may become more important than same-day headlines.

13. Bottom line

The cannabis rescheduling catalyst is real, but it is not as simple as “hearing equals approval.” The broader move from Schedule I to Schedule III depends on a legal and scientific record. The government enters with FDA/HHS analysis, medical-use arguments and Schedule III findings. The anti-rescheduling participants are trying to attack the weak points: abuse potential, CAMU, safety, product standardization, impaired driving, workplace testing, public safety and state-level implementation risk.

For $TLRY, $CGC, $ACB, $CRON and broader cannabis sentiment, the lesson is straightforward: the sector may move before the final legal answer, but the quality of the administrative record is what can decide whether the move has durability. A clean, defensible path toward broad Schedule III would be a major narrative reset. A messy record, narrow rule, delayed implementation or litigation overhang would leave the sector exposed to another round of headline volatility.

The most important thing to watch now is not only whether the anti-rescheduling parties speak. They will. The real question is whether their testimony creates enough doubt to weaken the government’s Schedule III foundation before the July 15 deadline.

Merlintrader educational editorial. Source links were reviewed for accuracy at the time of publication, but regulatory proceedings can change quickly. Official DEA, Federal Register and court or agency records should control over secondary interpretations.